Last reviewed · How we verify
gender affirming hormone therapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
gender affirming hormone therapy (gender affirming hormone therapy) — Celia Bañuls.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| gender affirming hormone therapy TARGET | gender affirming hormone therapy | Celia Bañuls | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- gender affirming hormone therapy CI watch — RSS
- gender affirming hormone therapy CI watch — Atom
- gender affirming hormone therapy CI watch — JSON
- gender affirming hormone therapy alone — RSS
Cite this brief
Drug Landscape (2026). gender affirming hormone therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/gender-affirming-hormone-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab